Enhancing cancer immunotherapy through polymer-based antibody conjugation technologies
Cancer immunotherapy has emerged as a transformative strategy with remarkable clinical potential. Therapeutic approaches, such as monoclonal immunotherapeutic antibodies, dual immune checkpoint blockade, and small-molecule immunomodulators, have demonstrated significant or promising benefits.
Authors
- Na Shen (ORCID: https://orcid.org/0000-0003-1557-1060)
- Silin Ye (ORCID: https://orcid.org/0000-0002-2735-7881)
- Jun Chen (ORCID: https://orcid.org/0000-0003-1330-9616)
- Hongyu Chu (ORCID: https://orcid.org/0000-0003-2991-7886)
- Xuedong Fang (ORCID: https://orcid.org/0000-0002-9925-6748)
- Zhaohui Tang (ORCID: https://orcid.org/0000-0003-4726-4305)
Institutions
- Yunnan University (CN)
- Jilin University (CN)
- Chinese Academy of Sciences (CN)
- Changchun Institute of Applied Chemistry (CN)
- State Key Laboratory of Polymer Physics and Chemistry (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2025-11-24
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2025.0512
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Chinese Academy of Sciences
- People's Government of Jilin Province
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- Youth Innovation Promotion Association